Our Work
Latham & Watkins Advises Mainstay Medical in US$125 Million Equity Financing Transaction
March 1, 2024
Firm represents the medical device company.
Mainstay Medical Holdings plc has announced an equity financing in which it will receive gross proceeds of US$125 million. Mainstay intends to use the funds to support the company’s continued commercial growth of ReActiv8® Restorative Neurostimulation in the US, Europe, and Australia, additional post-market clinical studies and research, and general operations.
Latham & Watkins LLP advised Mainstay Medical Holdings in the transaction with a corporate team led by San Diego partners Cheston Larson and Matt Bush, and counsel Evan Youngstrom, with associate Alex Stuart-Lovell.